The presynaptic component of the serotonergic system is required for clozapine's efficacy

Neuropsychopharmacology

Volumn 36, Issue 3, 2011, Pages 638-651

  Yadav, Prem N ^a   Abbas, Atheir I ^b   Farrell, Martilias S ^a   Setola, Vincent ^a,c   Sciaky, Noah ^a   Huang, Xi Ping ^a,c   Kroeze, Wesley K ^a   Crawford, Latasha K ^d   Piel, David A ^d   Keiser, Michael J ^e   Irwin, John J ^e   Shoichet, Brian K ^e   Deneris, Evan S ^b   Gingrich, Jay ^f   Beck, Sheryl G ^d   Roth, Bryan L ^a,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NONE   (United States)

Author keywords

antipsychotic drugs; clozapine; pet1; schizophrenia; serotonin

Indexed keywords

CLOZAPINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG EFFICACY; GENE DELETION; HEAD TWITCH; LOCOMOTION; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; STEREOTYPY;

ACOUSTIC STIMULATION; ACTION POTENTIALS; ADRENERGIC UPTAKE INHIBITORS; AMPHETAMINES; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; KETANSERIN; LYSINE; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEURONS; PATCH-CLAMP TECHNIQUES; PHENCYCLIDINE; PRESYNAPTIC TERMINALS; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RADIOLIGAND ASSAY; RAPHE NUCLEI; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN; SEROTONIN ANTAGONISTS; STARTLE REACTION; STEREOTYPED BEHAVIOR; TRITIUM; TRYPTOPHAN HYDROXYLASE;

EID: 78651410153     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.195     Document Type: Article

References (65)

1. Abbas AI, Yadav PN, Yao WD, Arbuckle MI, Grant SG, Caron MG et al (2009). PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci 29: 7124-7136.
2. Angst J, Jaenicke U, Padrutt A, Scharfetter C (1971). Ergebnisse eines Doppelblindversuches von HF 1854* (8-Chlor-11-(4-methyl-1-piperazinyl)-5H- dibenzo (b, e) (1,4) diazepin) im Vergleich zu Levomepromazin. Pharmacopsychiatry 4: 192-200.
3. Armbruster BN, Roth BL (2005). Mining the receptorome. J Biol Chem 280: 5129-5132.
4. Bakshi VP, Swerdlow NR, Geyer MA (1994). Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271: 787-794.
5. Beaulieu JM, Gainetdinov RR, Caron MG (2009). Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49: 327-347.
6. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V et al (2008). A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132: 125-136.
7. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG (2005). An Akt/beta-arrestin 2/ PP2A signaling complex mediates dopaminergic neurotransmis-sion and behavior. Cell 122: 261-273.
8. Beck SG, Pan YZ, Akanwa AC, Kirby LG (2004). Median and dorsal raphe neurons are not electrophysiologically identical. J Neurophysiol 91: 994-1005.
9. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y et al (2010). Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 13: 76 .
10. Bolden C, Cusack B, Richelson E (1992). Antagonism by anitmuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharm Exp Ther 260: 576-580.
11. Bressan RA, Erlandsson K, Stone JM, Mulligan RS, Krystal JH, Ell PJ et al (2005). Impact of schizophrenia and chronic anti-psychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo. Biol Psychiatry 58: 41-46.
12. Carlsson A, Waters N, Carlsson ML (1999). Neurotransmitter interactions in schizophrenia-therapeutic implications. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4): 37-43.
13. Conn PJ, Roth BL (2008). Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 33: 2048-2060.
14. Creese I, Burt DR, Snyder SH (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizo-phrenic drugs. Science 192: 481-483.
15. Enna SJ, Bennett Jr JP, Burt DR, Creese I, Snyder SH (1976). Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency. Nature 263: 338-341.
16. Fink H, Morgenstern R, Oelssner W (1984). ClozapineFa serotonin antagonist? Phamacol Biochem Behav 20: 513-517.
17. Geyer MA, Braff DL (1987). Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull 13: 643-668.
18. Gray JA, Roth BL (2007). The pipeline and future of drug development in schizophrenia. Mol Psychiatry 12: 904 .
19. Hendricks T, Francis N, Fyodorov D, Deneris ES (1999). The ETS domain factor Pet-1 is an early and precise marker of central serotonin neurons and interacts with a conserved element in serotonergic genes. J Neurosci 19: 10348-10356.
20. Hendricks TJ, Fyodorov DV, Wegman LJ, Lelutiu NB, Pehek EA, Yamamoto B et al (2003). Pet-1 ETS gene plays a critical role in 5-HT neuron development and is required for normal anxietylike and aggressive behavior. Neuron 37: 233-247.
21. Hert J, Keiser MJ, Irwin JJ, Oprea TI, Shoichet BK (2008). Quantifying the relationships among drug classes. J Chem Inf Model 48: 755-765.
22. Hippius H (1999). A historical perspective of clozapine. J Clin Psychiatry 60(Suppl 12): 22-23.
23. Hopkins AL, Groom CR (2002). The druggable genome. Nat Rev Drug Discov 1: 727-730.
24. James CA, Weininger D, Delaney J (1992). Daylight Theory Manual. Daylight Chemical Information Systems, Inc.: Mission Viejo, CA.
25. Javitt DC, Duncan L, Balla A, Sershen H (2005). Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry 10: 275-287.
26. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
27. Jensen P, Farago AF, Awatramani RB, Scott MM, Deneris ES, Dymecki SM (2008). Redefining the serotonergic system by genetic lineage. Nat Neurosci 11: 417-419.
28. Kane J, Honigfield G, Singer J, Meltzer HY (1988). Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789-796.
29. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical anti-psychotics?: A new hypothesis. Am J Psychiatry 158: 360-369.
30. Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, Lizardi-Ortiz JE et al (2010). Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci 31: 381-390.
31. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK (2007). Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25: 197-206.
32. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ et al (2009). Predicting new molecular targets for known drugs. Nature 462: 175-181.
33. Li Z, Prus AJ, Dai J, Meltzer HY (2009). Differential effects of M1 and 5-hydroxytryptamine1A receptors on atypical antipsychotic drug-induced dopamine efflux in the medial prefrontal cortex. J Pharmacol Exp Ther 330: 948-955.
34. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
35. Linnet K (2002). Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol 17: 233-238.
36. Magalhaes AC, Holmes KD, Dale LB, Comps-Agrar L, Lee D, Yadav PN et al (2010). CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci 13: 622-629.
37. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002). The protein kinase complement of the human genome. Science 298: 1912-1934.
38. Mansbach RS, Geyer MA (1989). Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2: 299-308.
39. Matsuoka S, Huang M, Elledge SJ (1998). Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282: 1893-1897.
40. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A et al (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60: 82-91.
41. Meltzer HY, Matsubara S, Lee J-C (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251: 238-246.
42. Meltzer HY, Okayli G (1995). Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152: 183-190.
43. Miller RJ, Hiley CR (1974). Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism. Nature (London) 248: 546-547.
44. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999). Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98: 427-436.
45. Nash JF, Meltzer HY, Gudelsky GA (1988). Antagonism of serotonin receptor mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. Eur J Pharmacol 151: 463-469.
46. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L et al (1998). Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol 355: 245-256.
47. Olah M, Bologa C, Oprea TI (2004). An automated PLS search for biologically relevant QSAR descriptors. J Comput Aided Mol Des 18: 437-449.
48. Oprea TI, Tropsha A, Faulon JL, Rintoul MD (2007). Systems chemical biology. Nat Chem Biol 3: 447-450.
49. Peroutka SJ, Lebovitz RM, Snyder SH (1981). Two distinct serotonin receptors with distinct physiological functions. Science 212: 827-829.
50. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF et al (2009). Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460: 748-752.
51. Rollema H, Lu Y, Schmidt AW, Zorn SH (1997). Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 338: R3-R5.
52. Roth BL, Ciaranello RD, Meltzer HY (1992). Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 260: 1361-1365.
53. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma Jr FJ, Shen Y et al (1994). Binding of typical and atypical antipsychotic agents to 5- hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268: 1403-1410.
54. Roth BL, Sheffler DJ, Kroeze WK (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3: 353-359.
55. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O et al (1997). Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presy-naptic and limbic selectivity. J Pharmacol Exp Ther 280: 83-97.
56. Schwieler L, Linderholm KR, Nilsson-Todd LK, Erhardt S, Engberg G (2008). Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci 83: 170-175.
57. Scott MM, Wylie CJ, Lerch JK, Murphy R, Lobur K, Herlitze S et al (2005). A genetic approach to access serotonin neurons for in vivo and in vitro studies. Proc Natl Acad Sci USA 102: 16472-16477.
58. Seeman P, Corbett R, Van Tol HH (1997). Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 16: 93-110, discussion 111-135.
59. Senn HJ, Jungi WF, Kunz H, Poldinger W (1977). Clozapine and agranulocytosis. Lancet 1: 547.
60. 0er I et al (2009). Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460: 753-757.
61. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D et al (2009). Common variants conferring risk of schizophrenia. Nature 460: 744-747.
62. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S et al (2008). Large recurrent microdeletions associated with schizophrenia. Nature 455: 232-236.
63. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB et al (2003). N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100: 13674-13679.
64. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB et al (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614. (Pubitemid 21912282)
65. Wittmann M, Marino MJ, Henze DA, Seabrook GR, Conn PJ (2005). Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases. J Pharmacol Exp Ther 313: 594-603.